Experimental gene injection aims to halt rare childhood blindness
NCT ID NCT05616793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The treatment is a one-time injection under the retina. The goal is to see if it is safe and can slow or stop vision loss. The study involves 22 participants aged 4 and older.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LCA5 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
-
University of Pennsylvania Perelman School of Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.